Recent observations from the above mentioned animal model [36] and from a clinical trial with a TG2 inhibitor [37] support the notion that TG2 is engaged in the pathogenesis of celiac disease, and that the catalytic activity of the enzyme is involved. The gene discussed is TGM2; the disease is celiac disease.